presentation to investors - mitsubishichem-hd.co.jp · pdf filepresentation to investors. ......

Click here to load reader

Post on 21-Aug-2018

215 views

Category:

Documents

0 download

Embed Size (px)

TRANSCRIPT

  • March 11, 2015

    Yoshimitsu KobayashiPresident & Chief Executive Officer

    Mitsubishi Chemical Holdings Corporation

    Step 2 (FY2013 - FY2015)

    Presentation to Investors

  • The forward-looking statements are based largely on information availableas of the date hereof, and are subject to risks and uncertainties which may be beyond Company control. Actual results could differ largely, due to numerous factors, including but not limited to the following: Group companies execute businesses in many different fields, such as information and electronics, performance products, polymers and processed products, pharmaceuticals, carbon and inorganic products, and petrochemicals, and these business results are subjected to influences of world demands, exchange rates, price and procurement volume of crude oil and naphtha, trends in market prices, speed in technology innovation, National Health Insurance price revision, product liabilities, lawsuits, laws, and regulations.

    2

  • List of Abbreviations

    MCHC: Mitsubishi Chemical Holdings CorporationMCC: Mitsubishi Chemical CorporationMTPC: Mitsubishi Tanabe Pharma CorporationMPI: Mitsubishi Plastics, Inc.MRC: Mitsubishi Rayon Co., Ltd.LSII: Life Science Institute, Inc.TNSC: Taiyo Nippon Sanso Corporation

    APIC: API CorporationBARDA: Biomedical Advanced Research

    and Development AuthorityCRK: Chuo Rika Kogyo CorporationHLC: Healthy Life Compass CorporationLSIM: LSI Medience CorporationNEDO: New Energy and Industrial Technology

    Development OrganizationNIMS: National Institute for Materials ScienceNSCI: The Nippon Synthetic Chemical Industry Co., Ltd.QKK: Qualicaps Co., Ltd.

    ALS: Amyotrophic lateral sclerosisBPA: Bisphenol-ACAE: Computer aided engineeringCD: Crohn's diseaseCIDP: Chronic inflammatory demyelinating

    polyradicaloneuropathy DPC: Diphenyl carbonateEO: Ethylene oxideEV: Electric vehicleEVOH: Ethylene vinyl alcoholFPD: Flat panel displayGaN: Gallium nitrideHEV: Electric vehicleHib: Haemophilus influenza type bICT: Information and communication technologyLiB: Lithium-ion batteryMMA: Methyl methacrylateMOCVD: Metal organic chemical vapor depositionMOS: Management of SustainabilityMOT: Management of TechnologyMS: Multiple sclerosis OLED: Organic light emitting diodeOPV: Organic photovoltaic

    FY2011: April 1, 2011 March 31, 2012FY2012: April 1, 2012 March 31, 2013FY2013: April 1, 2013 March 31, 2014FY2014: April 1, 2014 March 31, 2015FY2015: April 1, 2015 March 31, 2016

    Note: Product names, brand names, service names, and technology names used in this presentation material are denoted in italics and are trademarks or registered trademarks of the MCHC Group in Japan and/or overseas. Other product names, brand names, and service names may also be protected.

    PC: PolycarbonatePE: PolyethylenePCM: Prepreg compression moldingPHEV: Plug-in hybrid electric vehiclePHL: PhenolPMMA: Polymethyl methacrylatePP: PolypropylenePS: PsoriasisPTA: Terephthalic acidPVC: Polyvinyl chloridePVOH: Polyvinyl alcoholRTM: Resin transfer moldingSAP: Super absorbent polymerSBU: Strategic business unitSM: Styrene monomerSMC: Sheet molding compoundUTT: UtilityVLP: Virus-like particlesZEB: Zero energy building

    3

  • Todays Agenda

    1. Group Overview and Performance Review

    2. Progress in Principal Businesses (Comparison with Step 2)

    2-1. Performance Products

    2-2. Health Care

    2-3. Industrial Materials

    2-4. Summary

    3. Challenges of Formulating the Next Medium-term Management Plan

    4

  • *Listed company**Net sales, employees (as of March 31, 2014)

    The KAITEKI Institute, Inc.The KAITEKI Institute, Inc.

    MCHC* Net sales (consolidated): 3,498.8 billion**Employees (consolidated): 56,031**Oct. 2005

    Performance Products

    Health Care

    Industrial Materials

    Mitsubishi Chemical Holdings America, Inc.Mitsubishi Chemical Holdings America, Inc.

    Mitsubishi Chemical Holdings (Beijing) Co., Ltd.Mitsubishi Chemical Holdings (Beijing) Co., Ltd.

    Mitsubishi Chemical Holdings Europe GmbH Mitsubishi Chemical Holdings Europe GmbH

    Mitsubishi Chemical Holdings Corporate Staff, Inc.Mitsubishi Chemical Holdings Corporate Staff, Inc.

    Nov. 2010

    Nov. 2011

    Nov. 2012

    Apr. 2013

    MTPC*

    Business linesPerformance products,Industrial materials, etc.

    Business linesPharmaceuticals, etc.

    Business linesPlastic products, etc.

    Business linesChemical products,

    resins, fibers, carbon fiberand composite materials,

    membrane bioreactors, etc.

    Net sales (consolidated) 412.7 billion**

    Net sales (consolidated) 606.2 billion**

    Net sales (consolidated)442.7 billion**

    MCC MPIOct. 2005 Oct. 2007 Apr. 2008 Apr. 2010

    MRC

    Apr. 2009

    Net sales (consolidated)2,159.7 billion**

    LSII

    Business linesHealthcare and medical ICT, support for pharmaceutical development and advanced

    medication, etc.

    Apr. 2014

    MCHC R&D Synergy Center, Inc.MCHC R&D Synergy Center, Inc. Apr. 2014

    Net sales (consolidated)[118.7 billion]**

    56.3%

    1-1. Group Overview

    TNSC*

    Business linesIndustrial gases,

    electronics,medical, etc.

    Net sales (consolidated)522.7 billion**

    Oct. 2013: Strengthening capital and business alliance (ownership ratio: 27%)Sep. 30, 2014: Commenced TOBNov. 12, 2014: Completed payment Thereafter, TNSC became a consolidated subsidiary (with 50.6% MCHC ownership)

    100%100%100%100%

    100%

    50.6

    Nov. 2014

    Net sales (consolidated): Approx. 4 trillionOverseas sales ratio: Approx. 40%Employees (consolidated): Approx. 70,000Overseas employees: Approx. 23,000(Figures for fiscal 2014 were calculated as the simple summation of TNSC results with those of the Group.)

    5

  • Recording mediaInformation and electronics

    -related productsImaging supplies

    Inorganic chemicals

    Food ingredients

    Battery materials

    Fine chemicals

    Polymer processingproducts

    Composite materials

    Basic petrochemicals

    Chemical derivatives Synthetic fiber materials

    Carbon products

    Synthetic resins

    Clinical testing

    Diagnostic reagentsand instruments

    Pharmaceuticals

    Performance ProductsElectronics ApplicationsDesigned Materials

    Health Care

    ChemicalsPolymers

    Chemical fibersPharmaceutical formulationmaterials

    1-2. Business Domains

    Industrial Materials

    Health Care

    Industrial gases

    6

  • 2,909.0

    2,515.1

    3,166.8 3,208.2 3,088.6

    3,498.8 3,680.0

    8.2

    66.3

    226.5

    130.6

    90.2 110.5

    160.0

    0

    100

    200

    300

    400

    500

    0

    1,000

    2,000

    3,000

    4,000

    5,000

    FY2008 FY2009 FY2010 FY2011 FY2012 FY2013 FY2014

    Net salesOperating income

    1-3. Financial Results and Fiscal 2014 Outlook

    Net sales Operating income( billion)

    Forecasts

    Consolidated TNSC in 3Q fiscal 2014 through TOB

    Forecasting major increase in income in fiscal 2014 (+145% Y-o-Y) because of this and other factors

    (Figures announced Nov. 27, 2014)Notes:Includes effects of adopting uniform date for account closings in fiscal 2013: Net sales: 151.9 billion; Operating income: 3.9 billionIncludes effects of consolidating TNSC in fiscal 2014: Net sales: 275.0 billion; Operating income: 17.5 billion

    7

    TNSC

  • Designed Materials: Conditions firm Health Care: Conditions firm for pharmaceuticals and healthcare solutions Polymers: Outlook for major increase in income in MMA/PMMA

    Domains SegmentsFY2013 actual results

    FY2014 forecasts* Change

    Accumulated through 3Q**

    Targetattainment

    ratioComments

    Performance Products

    Electronics Applications (5.5) (2.0) +3.5 (2.3)

    Consolidation of TNSC (Chemicals)[3Q fiscal 2014]

    Outlook for inventory valuation loss* for naphtha and paraxylene in Chemicals and marginal gain* for polyolefin in Polymers[3Q and 4Q fiscal 2014]

    Outlook for increase in income in Designed Materials, Health Care, and Polymers

    *Overall impact: (Approx. 18.0 billion)

    DesignedMaterials 46.5 55.5 +9.0 41.7 75.1%

    Health Care Health Care 68.3 70.0 +1.7 70.7 101%

    IndustrialMaterials

    Chemicals 0.7 17.5 +16.8 2.2 12.6%

    Polymers 2.3 20.5 +18.2 13.7 66.8%

    Others 5.7 6.5 + 0.8 3.3 50.8%

    Corporate (7.5) (8.0) (0.5) (5.0)

    Total 110.5 160.0 + 49.5 124.3 77.7%

    Operating income ( billion)

    *Figures announced Nov. 27, 2014**Figures announced Feb. 4, 2015

    8

    1-4. Operating Income by Segment:Fiscal 2013 Actual Results vs. Fiscal 2014 Forecasts

    Includes effects of adopting uniform date for account closings in fiscal 2013: Net sales: 151.9 billion; Operating income: 3.9 billion)Includes effects of consolidating TNSC in fiscal 2014: Net sales: 275.0 billion; Operating income: 17.5 billion

    Notes:

  • 17.4

    41.0 (Accumulatedthrough 3Q:

    39.4)**

    85.0

    0

    20

    40

    60

    80

    100

    FY2012Actual

    FY2013Actual

    FY2014Forecasts

    FY2015Step 2 Plan

    Increase income by accelerating development of growth fields

    Operating income ( billion)

    2-1. Performance Products: Progress

    53.5*

    9

    Growth fields Lithium-ion battery materials

    Organic synthesis (NSCI)

    Polyester film

    Engineering plastics

    Carbon fiber and composite materials,

    etc.

    Performance Products

    *Figure announced Nov. 27, 2014**Figure announced Feb. 4, 2015

  • 2-1-1. Electronics Applications: Principal Businesses

    10

View more